Homologous recombination repair (HRR) genes
HRR genes encode proteins involved in high-fidelity DNA repair. Alterations across this gene group are clinically relevant for PARP inhibitor eligibility and cancer risk assessment.
Where this biomarker is used
Each approval combines this biomarker with a specific indication and therapy. Select a therapy in the tables below to open its FDA-defined testing pathway.
Approvals where Homologous recombination repair (HRR) genes is defined directly in the indication labeling.
| Indication | Biomarker criteria | Therapies |
|---|---|---|
Metastatic Castrate Resistant Prostate Cancer (mCRPC) Solid Tumor · Prostate |
|
Approvals defined at the solid tumor level where Homologous recombination repair (HRR) genes is part of the eligibility criteria.
No tumor-agnostic approvals are currently mapped for this biomarker.
Tests that measure this biomarker
These assays report Homologous recombination repair (HRR) genes as part of their validated menu. In many cases they are identified in FDA labeling as acceptable companion diagnostics for specific approvals.
Reports Homologous recombination repair (HRR) genes as part of its biomarker panel.